Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flow (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net loss $ (10,456,615) $ (11,858,471)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 156,565 56,229
Deferred rent 46,262 97,415
Share based compensation expense 2,803,018 2,239,259
Changes in operating assets and liabilities:    
Prepaid expenses 258,914 51,418
Other assets 5,081
Accounts payable (279,416) (134,009)
Accrued expenses - other liabilities (230,744) (1,120)
Net cash used in operating activities (7,702,016) (9,544,198)
Cash flows from investing activities:    
Purchases of leasehold improvements and lab equipment (535,916) (823,886)
Net cash used in investing activities (535,916) (823,886)
Cash flows from financing activities:    
Net proceeds from issuance of series B convertible preferred stock 7,056,250
Net proceeds from exercise of warrants 14,834,344
Net proceeds from ATM sales 739,155 641,510
Payments of capital lease liability (36,769) (9,383)
Payments on note payable (250,173) (203,164)
Net cash provided by financing activities 7,508,463 15,263,307
Net increase (decrease) in cash, cash equivalents and restricted cash (729,469) 4,895,223
Cash, cash equivalents and restricted cash at beginning of period 7,997,937 4,797,060
Cash, cash equivalents and restricted cash at end of period 7,268,468 9,692,283
Supplemental non-cash financing and investing activities:    
Conversion of preferred stock  
Warrants issued to placement agent 89,581
Stock dividend accrual 587,143 608,343
Stock dividends issued and converted to common stock 14,000 5,200
Note payable for insurance premiums 399,683 383,030
Additional paid-in-capital for modification of warrants 16,741,356
Equipment acquired under capital lease 147,940 49,935
Liability of payment of leasehold improvements by landlord 286,720
Unearned restricted stock grants 126,100 381,333
Series A Preferred Stock [Member]    
Supplemental non-cash financing and investing activities:    
Conversion of preferred stock 133,139 350,412
Series B Preferred Stock [Member]    
Supplemental non-cash financing and investing activities:    
Conversion of preferred stock $ 868,022